Clinical Trial Update: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions [Phase 3]

View source ↗

Summary

This Phase 3 trial compares luspatercept against placebo in patients with myeloproliferative neoplasm-associated myelofibrosis who are on JAK2 inhibitors and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Myelofibrosis
• Myeloproliferative Neoplasms
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Luspatercept (luspatercept)

Snippet

Sponsor: Celgene | Conditions: Myeloproliferative Disorders, Myelofibrosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING